Citadel Advisors’s Entera Bio ENTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$273K Buy
245,577
+205,347
+510% +$288K ﹤0.01% 10688
2025
Q4
$78K Buy
40,230
+252
+0.6% +$591 ﹤0.01% 11812
2025
Q3
$76.8K Buy
39,978
+28,322
+243% +$54.2K ﹤0.01% 11998
2025
Q2
$22.1K Buy
+11,656
New +$23K ﹤0.01% 12083
2024
Q4
Sell
-20,553
Closed -$39.1K 14718
2024
Q3
$39.1K Buy
+20,553
New +$36.5K ﹤0.01% 12166
2024
Q2
Sell
-12,502
Closed -$20.9K 14525
2024
Q1
$20.9K Buy
+12,502
New +$13.8K ﹤0.01% 12987
2023
Q4
Sell
-15,368
Closed -$10.5K 14503
2023
Q3
$11.1K Buy
15,368
+15,336
+47,925% +$11.3K ﹤0.01% 13024
2023
Q2
$27 Buy
+32
New +$27 ﹤0.01% 14241
2023
Q1
Sell
-30,465
Closed -$30.4K 14893
2022
Q4
$22.2K Buy
+30,465
New +$22.1K ﹤0.01% 13059
2022
Q3
Sell
-12,657
Closed -$19.1K 12862
2022
Q2
$17K Sell
12,657
-2,400
-16% -$5.33K ﹤0.01% 12457
2022
Q1
$43K Sell
15,057
-12,531
-45% -$30.1K ﹤0.01% 12893
2021
Q4
$78K Sell
27,588
-12,270
-31% -$46K ﹤0.01% 12960
2021
Q3
$188K Sell
39,858
-27,312
-41% -$140K ﹤0.01% 12070
2021
Q2
$402K Buy
+67,170
New +$248K ﹤0.01% 10545
2020
Q4
Sell
-22,020
Closed -$28K 11051
2020
Q3
$28K Buy
+22,020
New +$33.4K ﹤0.01% 9783

Other funds holding ENTX

Citadel Advisors's ENTX Position: Q1 2026 in Review

Citadel Advisors increased its Entera Bio (ENTX) stake by 510% in Q1 2026, buying an estimated $288K and bringing the position to 245,577 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #10688.

Citadel Advisors first reported a position in ENTX in Q3 2020 and has held it in 15 quarters since. The position peaked at $402K in Q2 2021. 26 funds tracked by Wall St. Rank hold ENTX as of Q1 2026.

  • Citadel Advisors held 245,577 shares of Entera Bio worth $273K as of Q1 2026.
  • Citadel Advisors bought 205,347 Entera Bio shares in Q1 2026, an estimated $288K.
  • Entera Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #10688 holding.
  • Citadel Advisors first reported a position in Entera Bio in Q3 2020 and has held it in 15 quarters since.
  • Citadel Advisors's Entera Bio position peaked at $402K in Q2 2021.
  • 26 funds tracked by Wall St. Rank held Entera Bio as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.